IO Biotech, Inc. (IOBTQ): Nasdaq/NYSE listing notice — IO Biotech receives Nasdaq MVLS deficiency notice; 180 days to comply

IO Biotech, Inc.

Notice received Feb 12, 2026; MVLS below $50M for 30 consecutive business days.
Company has until August 11, 2026 to regain compliance.
Stock continues trading on Nasdaq Global Select Market during cure period.
If not cured, Nasdaq will issue delisting notice; company may appeal.
No assurance of regaining compliance with MVLS or other listing rules.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

IO Biotech, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A)

Exact text from the filing

February 12, 2026, IO Biotech, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the continued listing requirements for The Nasdaq Global Select Market because the market value of the Company’s listed securities (“MVLS”) was below the minimum of $50 million for a period of 30 consecutive business days, as required by Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Gl

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

IO Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-051790

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.